Medivation and Astellas Pharma announce TNBC Phase 2 trials

Medivation and Astellas Pharma have announced Phase 2 of TNBC trials.

Medivation and Astellas Pharma have announced the enrolment of its first patient in a new Phase 2 clinical trial for the treatment of triple negative breast cancer (TNBC).

David Hung, president and chief executive officer of Medivation, said that this was an important high point in the trials, as they are looking to extend itsenzalutamide development programme beyond prostate cancer and now into TNBC.

In this area, there is a significant amount of "unmet medical need", the expert highlighted. This is why such trials are extremely important.

"We plan to present the results from the Phase 1 study in breast cancer at an upcoming scientific conference," Dr Hung added.

It is envisaged that the second phase will enrol around 80 patients with TNBC across the world.

"The primary endpoint of the trial is clinical benefit rate, defined as the proportion of patients with a best response of complete response, partial response or stable disease at 16 weeks," an official release stated.

"All patients will receive enzalutamide at a dose of 160 mg to be taken orally once daily."